Executive Summary

Two numbers define a supply chain opportunity most supplement brands have not yet priced in.

Approximately 15–20 million Americans are currently prescribed GLP-1 receptor agonists (IQVIA prescription data, Q4 2025), and 48% of the U.S. adult population already falls below the Estimated Average Requirement for magnesium (NHANES 2013–2016, NIH Office of Dietary Supplements). These two facts define a specific formulation and sourcing challenge that supplement brands are now racing to address.

1. The GLP-1 Market: Scale and Sourcing Implications

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have moved beyond their original diabetes indication into mainstream weight management.

  • GLP-1 prescriptions in the U.S. grew approximately 40% year-over-year in 2025 (Epocrates 2025 Market Landscape Report)
  • An estimated 15–20 million Americans are actively using GLP-1 receptor agonists (IQVIA National Prescription Audit, Q4 2025)
  • Global GLP-1 drug revenue surpassed $50 billion in 2025 (Novo Nordisk and Eli Lilly FY2025 earnings reports)

The Magnesium Market Context. The global magnesium supplement market was valued at approximately $980 million in 2025 and is projected to grow at a CAGR of 6.7% through 2030 (Grand View Research, 2025). Magnesium glycinate specifically was valued at $542.5 million in 2024 with a CAGR of 5.7% through 2031 (SkyQuest Technology Group, Report ID: SQMR5597).

Sports Nutrition Validation. Beck et al. (2021, PMID: 34662692) reviewed micronutrient supplementation in athletic performance, documenting magnesium's role in energy metabolism and muscle function. The CRN 2024 Consumer Survey indicates magnesium is in 34% of pre-workout formulations in the U.S.

2. The Physiological Basis: Why Magnesium Matters for GLP-1 Users

GLP-1 receptor agonists mimic the incretin hormone, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. This creates a physiological environment that affects mineral absorption — particularly magnesium — through three interconnected mechanisms:

First, delayed gastric emptying alters transit time in the small intestine, the primary site of magnesium uptake (Barbagallo, Veronese and Dominguez, 2021; PMID: 33573164).

Second, clinical trial data from the STEP program show that up to 43.9% of semaglutide users experience nausea, particularly during dose escalation (Wilding JPH et al., NEJM, 2021; PMID: 33567185) — symptoms that contribute to mineral loss and reduced dietary intake.

Third, GLP-1 users typically consume 30–50% fewer calories than baseline. Since dietary magnesium comes primarily from whole grains, nuts, legumes, and leafy greens, reduced food volume directly translates to reduced magnesium intake.

The baseline deficiency problem amplifies this risk. Globally, inadequate magnesium intake affects an estimated 2.4 billion people (Zhang W and Zhao Y, 2025; PMID: 41504160). In the United States, approximately 48% of the adult population consumes less than the EAR for magnesium. A GLP-1 user who already had marginal magnesium status before starting medication — which describes roughly half of the U.S. adult population — enters a caloric deficit with a pre-existing mineral gap.
Biological RoleRelevance for GLP-1 Users
Neuromuscular signal transmissionMay affect muscle excitability and recovery
Cofactor in 300+ enzymatic reactions (incl. ATP)Energy metabolism depends on adequate magnesium
Cardiac electrical stabilityRelevant for GLP-1 users with cardiovascular risk factors
GABA and glutamate neurotransmitter modulationNeurotransmitter balance affected by mineral status
Supports melatonin regulation and nervous system relaxationSleep quality is a common concern among GLP-1 users
60% of body magnesium stored in boneChronic insufficiency may affect skeletal integrity

Note: This table describes physiological roles of magnesium. It does not constitute a health claim. Statements have not been evaluated by the FDA.

3. Magnesium Form Selection: A Procurement Decision Framework

Not all magnesium forms perform equally. The procurement decision should weigh elemental content, bioavailability, and GI tolerability simultaneously — a high elemental load with zero tolerability is a formulation dead end.

3.1 Comparative Specifications

FormElem.MgBioavailabilityGI ToleranceRecommended ForNotes
Magnesium Bisglycinate~14%High (~80%)ExcellentDaily use; GLP-1 companion; sleep supportChelated form; absorbed via dipeptide transporters (Pardo 2021, PMID:34111673)
Magnesium Citrate~16%Moderate (~25%)Moderate — osmotic laxative at higher dosesShort-term use; bowel regularityOsmotic effect drives GI side effects
Magnesium Oxide~60%Low (~4%)Poor — strong laxative effect commonBudget formulations; not for GLP-1 usersHigh dropout rate in clinical use
Magnesium L-Threonate~8%ModerateGoodCognitive support; brain-specific formulationsLow elemental yield; higher cost per mg
Magnesium Taurate~9%GoodGoodCardiovascular formulationsPromising cardiovascular research

Sources: Pardo et al., Nutrition, 2021 (PMID: 34111673); Barbagallo, Veronese and Dominguez, Nutrients, 2021 (PMID: 33573164); Schuette et al., JPEN, 1994 (PMID: 7815675).

3.2 Why Bisglycinate Is Preferred for GLP-1 Companion Formulations

1. Alternative Absorption Pathway. Chelation allows absorption through amino acid transport pathways rather than passive mineral channels. For GLP-1 users with altered gastric motility, this is clinically relevant. Schuette et al. (1994, PMID: 7815675) reported magnesium diglycinate achieved approximately double the absorption of magnesium oxide (23.5% vs. 11.8%, p<0.05) via dipeptide transport pathways.

2. GI Tolerability. Magnesium bisglycinate does not typically cause loose stools or cramping at recommended doses, unlike oxide or citrate forms. For a user population with baseline nausea rates of 43.9%, tolerability is not a nice-to-have — it is a compliance prerequisite.

3. No Known Drug Interactions. According to Drugs.com, magnesium bisglycinate has no known interactions with semaglutide or tirzepatide (accessed June 2026).

4. Glycine Co-Factor Contribution. Glycine participates in inhibitory neurotransmitter activity and serves as a building block for glutathione synthesis. Kawai et al. (2014, PMID: 25533534) demonstrated glycine ingestion before bedtime at 3 g improves subjective sleep quality through NMDA receptor modulation.

Formulation note: At 14% elemental magnesium, a typical 200 mg dose requires approximately 1.43 g of magnesium bisglycinate, delivering roughly 1.0–1.2 g of glycine — below the 3 g dose used in Kawai et al. Brands targeting glycine's sleep mechanism should evaluate total glycine delivery per serving.

3.3 Where This Analysis Has Gaps

Cost Disparity. Magnesium oxide costs roughly 1/5 to 1/8 of bisglycinate per kilogram of elemental magnesium. For brands targeting price-sensitive retail channels, the oxide-to-bisglycinate cost jump may not be absorbable without compromising margin.

No GLP-1-Specific Clinical Trials. Every reference in this article connects magnesium's known physiological roles to GLP-1's documented effects. The logical chain is sound, but it is an inference chain — not a set of direct RCTs testing magnesium supplementation in GLP-1 users.

Competition from Multi-Mineral Formulations. Some brands are taking a broader approach, combining magnesium with calcium, zinc, vitamin D, and electrolytes in a single GLP-1 support formula.

4. GLP-1 Companion Formulation: Product Concept

IngredientRationaleRegulatory Note
Magnesium Bisglycinate (200–400 mg)Core mineral; high bioavailability; GI-friendlyStructure/function claim (US)
Vitamin D3 + K2Bone density supportFDA health claim (Vit D)
B-Complex (B6, B12, Folate)Energy metabolismStructure/function claims
ZincImmune functionStructure/function claim
Electrolyte blendDehydration risk managementStructure/function claims
Probiotic strainsGut healthStrain-specific evidence required

5. Regulatory and Compliance

Compliant (Structure/Function)Prohibited (Disease Claims)
Supports healthy insulin sensitivityTreats diabetes
Helps maintain healthy blood sugar metabolism already in normal rangePrevents metabolic syndrome
Helps maintain muscle comfort and recoveryCures muscle cramps
Promotes restful sleepTreats insomnia
Supports healthy cardiovascular functionPrevents heart disease
⚠ Regulatory Note on "GLP-1 Companion" Language: "GLP-1 companion supplement" is a market positioning term, not a regulatory category recognized by the FDA, EFSA, TGA, or Health Canada. No regulatory body has defined a "companion supplement" pathway for prescription drugs. Brands should consult regulatory counsel before using this language on product labels.

6. Frequently Asked Questions: Procurement and Formulation

Q1: What bioavailability data should I request?

Request comparative data against at least one reference form (typically magnesium oxide or citrate). Peer-reviewed studies such as Pardo et al. (2021, PMID: 34111673) and Schuette et al. (1994, PMID: 7815675) provide benchmarks.

Q2: What should a Certificate of Analysis (COA) include?

  • Identity confirmation (FTIR or equivalent)
  • Elemental magnesium content (% w/w)
  • Chelation ratio (90%+ recommended, 95%+ optimal)
  • Heavy metals panel (Pb, As, Cd, Hg per USP)
  • Microbial limits
  • Loss on drying
  • Particle size distribution

Q3: How do I evaluate batch-to-batch consistency?

Request at least 3 consecutive batch COAs. Compare elemental magnesium variance (within 5%), chelation ratio consistency, heavy metals trends, and microbial counts.

Q4: What MOQs and lead times should I expect?

Standard MOQs: 100–500 kg initial orders. Lead times: 2–4 weeks in-stock, 6–8 weeks custom. Pilot quantities (10–25 kg) may be available at premium.

Q5: What certifications should I look for?

cGMP (FDA-registered), ISO 9001, Halal/Kosher if applicable, FSSC 22000 or ISO 22000, third-party audits (NSF/USP/SGS).

7. Supplier Evaluation Checklist

Quality: cGMP (FDA-registered) | ISO 9001 | FSSC 22000 | Third-party audits | USP heavy metals testing | Stability data | Allergen controls

Documentation: COA per batch | TDS | SDS | Regulatory compliance letters | Chelation ratio documentation (90%+)

Supply Chain: MOQ flexibility | Written lead time | Batch consistency (3+ batches) | Traceability | Contingency plan

Commercial: Documentation transparency | COA availability | Technical support | Regulatory support | Payment terms

8. Key Takeaway

Magnesium bisglycinate offers superior GI tolerability and amino-acid-mediated absorption compared to oxide and citrate forms (Schuette et al., 1994: 23.5% vs. 11.8% absorption, p<0.05), making it the preferred mineral form for GLP-1 companion formulations. With 48% of U.S. adults below the EAR for magnesium and 15–20 million Americans now on GLP-1 receptor agonists, the addressable market for high-bioavailability mineral replenishment is expanding rapidly.

References

Core Evidence:

  1. Zhang W, Zhao Y. (2025). Global Dietary Magnesium Deficiency. Int J Vitam Nutr Res. PMID: 41504160.
  2. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 384(11), 989–1002. PMID: 33567185.
  3. Pardo MR, et al. (2021). Bioaccessibility and Bioavailability of Magnesium. Nutrients, 13(9), 3172. PMID: 34111673.
  4. Barbagallo M, et al. (2021). Magnesium in Aging, Health and Diseases. Nutrients, 13(2), 463. PMID: 33573164.
  5. Schuette SA, et al. (1994). Bioavailability of Magnesium Diglycinate vs Magnesium Oxide. JPEN, 18(5), 430–435. PMID: 7815675.
  6. Kawai N, et al. (2014). The Sleep-Promoting Effects of Glycine. Neuropsychopharmacology, 39, 1915–1925. PMID: 25533534.

Market Data:

  1. Grand View Research. Magnesium Supplement Market Report, 2025–2030. 2025.
  2. SkyQuest Technology Group. Magnesium Glycinate Market 2024–2031. Report ID: SQMR5597.
  3. IQVIA. National Prescription Audit, Q4 2025.
  4. Novo Nordisk and Eli Lilly. Annual Earnings Reports, FY2025.